RELMADA THERAPEUTICS, INC. current report, 23 February 2022

Full document

Business Context and Reporting Period

This Form 8-K was filed by Relmada Therapeutics, Inc. on February 23, 2022. The company is a clinical-stage biopharmaceutical firm incorporated in Nevada, with principal executive offices in Coral Gables, Florida. Its common stock trades on the NASDAQ under the symbol RLMD.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosures regarding clinical trial results rather than financial performance data.

Material Changes and Events

  • Item 7.01 (Regulation FD Disclosure): The Company announced top-line results from its Human Abuse Potential (HAP) study for REL-1017, a novel NMDA receptor channel blocker.
  • Lead Candidate Status: REL-1017 is the Company's lead candidate currently in Phase 3 development for the treatment of major depressive disorder (MDD).
  • Study Comparison: The HAP study compared REL-1017 against Ketamine.
  • Item 8.01 (Other Events): The Company updated its corporate presentation on the same date.

Guidance, Outlook, and Management Commentary

Management held a conference call and webcast on February 23, 2022, at 8:30 AM Eastern Time to discuss the study results. The filing incorporates by reference the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) containing detailed commentary. The filing text itself does not contain specific forward-looking guidance, risk factors, or contingency details beyond the announcement of the study results.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for the specific statistical outcomes of the REL-1017 HAP study versus Ketamine.
  • Examine Exhibit 99.2 (Slide Presentation) for detailed data on the abuse potential profile of the lead candidate.
  • Verify the Phase 3 development timeline for REL-1017 in the treatment of major depressive disorder (MDD) in Exhibit 99.3 (Corporate Presentation).
  • Check subsequent filings for any regulatory feedback from the FDA regarding the HAP study results.